Table 2. Clinical parameters and outcomes of the comprised research.
OSA: obstructive sleep apnea; OSAS: obstructive sleep apnea syndrome; PSG: polysomnography; ESS: Epworth sleepiness scale; OBES: obesity; BMI: body mass index; ACS: acute coronary syndrome; NM: not mentioned; JBI: Joanna Briggs Institute
| Study ID | OSA diagnostic tool | Obesity cut-off point | Mean BMI (kg/m2) | Prevalence of OSA (%) | Main outcomes | JBI |
| AlAteeq et al., 2024 [10] | SLEEP-50 questionnaire | NM | NM | 67 (17.7%) | Obese adults have a significant prevalence of sleep problems. Multiple co-occurring sleep disorders were observed in a considerable number of persons with sleep disorders, and there was a significant correlation between these conditions and obesity and overweight. | Moderate |
| van Ede et al., 2024 [11] | The OBES-questionnaire | >30 | 42.4 ± 4.5 | 422 (17.3%) | Because years of OSAS without a diagnosis were not taken into account, a negative correlation was discovered for OSAS incidence. Furthermore, there was no correlation found between OBES and blood markers associated with poor metabolism when obesity-related comorbidities were absent. | Moderate |
| Dixit et al., 2024 [12] | PSG | NM | 32 ± 2 | 5 (15.2%) | It was discovered that the proportion of obese patients with obstructive sleep apnea-hypopnea syndrome was comparable to other studies carried out in comparable environments. | High |
| Brikman et al., 2024 [13] | NM | >30 | 42.1 ± 6.3 | 22 (12.6%) | NM | High |
| Hao et al., 2023 [14] | PSG | >30 | 48.4 ± 12.6 | 184 (88.9%) | Males were the only significant contributory factor and females were the protective factor against severe OSA in individuals with a BMI > 35 kg/m2. | Moderate |
| Hao et al., 2023 [15] | ESS | >25 | 31.0 ± 2.5 | 485 (76.5%) | Given the frequent coexistence of obesity and OSA, it is crucial to take into account their proportional risk of cardiovascular events as well as how they interact. According to this study, OSA considerably raised the chance of cardiovascular events following ACS, even in patients who were not obese. | Moderate |
| Agossou et al., 2023 [16] | PSG | >30 | 45.2 ± 8.7 | 106 (74.1%) | NM | Moderate |